Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Brain Neoplasms 3Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 72Cisplatin 57Cetuximab 38Fluorouracil 25Nivolumab 21Radiotherapy 20Carboplatin 19Paclitaxel 14Docetaxel 11Cyclophosphamide 9Gefitinib 8fludarabine 7durvalumab 7zalutumumab 6atezolizumab 6Drug Therapy 6Bleomycin 6epacadostat 5cemiplimab 5Radiotherapy, Intensity-Modulated 5Pemetrexed 5Ipilimumab 5Gemcitabine 5Afatinib 5spartalizumab 4Standard of Care 4Radiation 4Injections 4Immune Checkpoint Inhibitors 4Fibroblast Growth Factor 7 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Head and Neck Neoplasms × 5-fluoropentyl-2-methylmalonic acid × Clear all
NCT01260480 2010-12-17

An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation

Aposense Ltd.

Phase 2 Unknown
60 enrolled
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡